Whilst it may not be a huge deal, we thought it was good to see that the Cardiff Oncology, Inc. (NASDAQ:CRDF) Chief Financial Officer, James Levine, recently bought US$37k worth of stock, for US$4.76 per share. While we're hesitant to get too excited about a purchase of that size, we do note it increased their holding by a solid 13%.

Cardiff Oncology Insider Transactions Over The Last Year

Over the last year, we can see that the biggest insider purchase was by Independent Director Gary Pace for US$940k worth of shares, at about US$2.60 per share. We do like to see buying, but this purchase was made at well below the current price of US$4.26. Because the shares were purchased at a lower price, this particular buy doesn't tell us much about how insiders feel about the current share price.

While Cardiff Oncology insiders bought shares during the last year, they didn't sell. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!

There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of undervalued small cap companies that insiders are buying.

Does Cardiff Oncology Boast High Insider Ownership?

Many investors like to check how much of a company is owned by insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Insiders own 2.6% of Cardiff Oncology shares, worth about US$6.0m, according to our data. Overall, this level of ownership isn't that impressive, but it's certainly better than nothing!

So What Do The Cardiff Oncology Insider Transactions Indicate?

The recent insider purchases are heartening. And an analysis of the transactions over the last year also gives us confidence. But on the other hand, the company made a loss during the last year, which makes us a little cautious. On this analysis the only slight negative we see is the fairly low (overall) insider ownership; their transactions suggest that they are quite positive on Cardiff Oncology stock. While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. To that end, you should learn about the 5 warning signs we've spotted with Cardiff Oncology (including 3 which are potentially serious).

Of course Cardiff Oncology may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.